Comparison of levels BNP and NT-proBNP between heart failure patients and heart failure with COVID-19

Comprehensive studies have been undertaken on biomarkers linked to coronavirus illness 2019 (COVID-19) in both healthy persons and those with diverse disorders, including cardiovascular diseases. The aim of the current study was to investigate B-Type Natriuretic Peptide (BNP), N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP), Cardiac troponin, and certain cytokines, including Interleukin-10 (IL-10), Interleukin-12 (IL-12), and Tumor Necrosis Factors (TNF-α). Study was conducted from January 2022 to August 2022, with participants aged 18 to 68 years. The total number of subjects was 90 individuals: 35 patients with heart failure (G1), 33 of whom had heart failure with COVID-19 (G2), and 22 in the control group (G3). The specimens were obtained from General Kirkuk Hospital and Azadi Teaching Hospital. BNP (brain natriuretic peptide), NT-proBNP (N-terminal pro-BNP), IL-12, IL-10, and TNF-α. The present study showed increase NT-proBNP increased in both G1 and G2 as compared with G3 that were (216.39±24.43, 213.35±22.0, 169.50±23.30) respectively, at P-value <0.001. While BNP highly increased in G2, followed in G2 groups and decreased in control that were (172.25±21.46, 140.66 ± 21.24, 85.84 ± 26.89) respectively, at P-value <0.001. IL-12, TNF-a, IL-10 in G2 were (451.19±13.5, 144.1± 71.2, 192.0±25.5 ) as compared with control that were (350.07±22.03, 104.1± 144.1± 119.22±29.6)at p-value<0.05, This study found that covid-19 patients have higher NT-proBNP, BNP and interleukin-10,-12, and TNF-a levels, which indicate illness progression.